25 XP   0   0   10

Ascelia Pharma AB (publ)
Buy, Hold or Sell?

Let's analyse Ascelia together

PenkeI guess you are interested in Ascelia Pharma AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ascelia Pharma AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ascelia Pharma AB (publ)

I send you an email if I find something interesting about Ascelia Pharma AB (publ).

Quick analysis of Ascelia (30 sec.)










What can you expect buying and holding a share of Ascelia? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr2.20
Expected worth in 1 year
kr-0.95
How sure are you?
26.1%

+ What do you gain per year?

Total Gains per Share
kr-3.16
Return On Investment
-24.7%

For what price can you sell your share?

Current Price per Share
kr12.76
Expected price per share
kr8.5 - kr17.48
How sure are you?
50%

1. Valuation of Ascelia (5 min.)




Live pricePrice per Share (EOD)

kr12.76

Intrinsic Value Per Share

kr-10.74 - kr-11.38

Total Value Per Share

kr-8.54 - kr-9.18

2. Growth of Ascelia (5 min.)




Is Ascelia growing?

Current yearPrevious yearGrowGrow %
How rich?$6.8m$21.8m-$12.3m-131.8%

How much money is Ascelia making?

Current yearPrevious yearGrowGrow %
Making money-$2.5m-$3m$503.9k20.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Ascelia (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#715 / 1011

Most Revenue
#901 / 1011

Most Profit
#328 / 1011

Most Efficient
#345 / 1011

What can you expect buying and holding a share of Ascelia? (5 min.)

Welcome investor! Ascelia's management wants to use your money to grow the business. In return you get a share of Ascelia.

What can you expect buying and holding a share of Ascelia?

First you should know what it really means to hold a share of Ascelia. And how you can make/lose money.

Speculation

The Price per Share of Ascelia is kr12.76. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ascelia.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ascelia, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr2.20. Based on the TTM, the Book Value Change Per Share is kr-0.79 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.56 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ascelia.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.03-0.2%-0.07-0.6%-0.09-0.7%-0.07-0.6%-0.06-0.5%
Usd Book Value Change Per Share-0.03-0.2%-0.07-0.6%-0.05-0.4%0.000.0%0.010.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.03-0.2%-0.07-0.6%-0.05-0.4%0.000.0%0.010.1%
Usd Price Per Share0.31-0.89-1.78-2.19-1.90-
Price to Earnings Ratio-2.68--2.81--5.73--8.66--7.53-
Price-to-Total Gains Ratio-11.11--11.52--7.66--14.97--14.97-
Price to Book Ratio1.53-3.01-2.77-3.33-2.89-
Price-to-Total Gains Ratio-11.11--11.52--7.66--14.97--14.97-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.172644
Number of shares852
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.070.00
Usd Total Gains Per Share-0.070.00
Gains per Quarter (852 shares)-61.77-3.10
Gains per Year (852 shares)-247.09-12.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-247-2570-12-22
20-494-5040-25-34
30-741-7510-37-46
40-988-9980-50-58
50-1235-12450-62-70
60-1483-14920-74-82
70-1730-17390-87-94
80-1977-19860-99-106
90-2224-22330-111-118
100-2471-24800-124-130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.023.00.00.0%0.023.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%6.016.01.026.1%6.016.01.026.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.023.00.0%0.00.023.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%6.016.01.026.1%6.016.01.026.1%

Fundamentals of Ascelia

About Ascelia Pharma AB (publ)

Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. It has two drug candidates in clinical development, which include Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, which is in Phase 2 trial for the treatment of gastric cancer. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.

Fundamental data was last updated by Penke on 2024-04-19 00:37:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ascelia Pharma AB (publ).

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ascelia earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Ascelia to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ascelia Pharma AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.1%+196.1%
TTM--211.9%+211.9%
YOY--277.7%+277.7%
5Y--432.9%+432.9%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Ascelia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ascelia to the Biotechnology industry mean.
  • -12.2% Return on Assets means that Ascelia generated kr-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ascelia Pharma AB (publ):

  • The MRQ is -12.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.2%TTM-20.4%+8.2%
TTM-20.4%YOY-13.0%-7.4%
TTM-20.4%5Y-11.4%-9.0%
5Y-11.4%10Y-10.7%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.2%-13.3%+1.1%
TTM-20.4%-12.7%-7.7%
YOY-13.0%-11.8%-1.2%
5Y-11.4%-14.0%+2.6%
10Y-10.7%-15.9%+5.2%
1.1.3. Return on Equity

Shows how efficient Ascelia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ascelia to the Biotechnology industry mean.
  • -14.3% Return on Equity means Ascelia generated kr-0.14 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ascelia Pharma AB (publ):

  • The MRQ is -14.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.3%TTM-25.8%+11.5%
TTM-25.8%YOY-15.0%-10.8%
TTM-25.8%5Y-13.2%-12.6%
5Y-13.2%10Y-12.3%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.3%-16.9%+2.6%
TTM-25.8%-16.0%-9.8%
YOY-15.0%-15.1%+0.1%
5Y-13.2%-19.7%+6.5%
10Y-12.3%-20.5%+8.2%

1.2. Operating Efficiency of Ascelia Pharma AB (publ).

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ascelia is operating .

  • Measures how much profit Ascelia makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ascelia to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ascelia Pharma AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM--224.4%+224.4%
YOY--288.3%+288.3%
5Y--479.5%+479.5%
10Y--625.2%+625.2%
1.2.2. Operating Ratio

Measures how efficient Ascelia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Ascelia Pharma AB (publ):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.110-3.110
TTM-3.266-3.266
YOY-3.783-3.783
5Y-5.657-5.657
10Y-7.783-7.783

1.3. Liquidity of Ascelia Pharma AB (publ).

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ascelia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.30 means the company has kr2.30 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Ascelia Pharma AB (publ):

  • The MRQ is 2.303. The company is able to pay all its short-term debts. +1
  • The TTM is 2.619. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.303TTM2.619-0.316
TTM2.619YOY7.674-5.055
TTM2.6195Y11.022-8.403
5Y11.02210Y10.639+0.383
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3033.905-1.602
TTM2.6194.212-1.593
YOY7.6745.337+2.337
5Y11.0226.062+4.960
10Y10.6396.401+4.238
1.3.2. Quick Ratio

Measures if Ascelia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ascelia to the Biotechnology industry mean.
  • A Quick Ratio of 1.93 means the company can pay off kr1.93 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ascelia Pharma AB (publ):

  • The MRQ is 1.935. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.440. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.935TTM2.440-0.506
TTM2.440YOY7.391-4.951
TTM2.4405Y12.322-9.882
5Y12.32210Y11.684+0.637
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9353.572-1.637
TTM2.4404.001-1.561
YOY7.3915.364+2.027
5Y12.3226.009+6.313
10Y11.6846.287+5.397

1.4. Solvency of Ascelia Pharma AB (publ).

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ascelia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ascelia to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Ascelia assets are financed with 14.6% credit (debt) and the remaining percentage (100% - 14.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ascelia Pharma AB (publ):

  • The MRQ is 0.146. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.198. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.146TTM0.198-0.051
TTM0.198YOY0.111+0.086
TTM0.1985Y0.098+0.099
5Y0.09810Y0.091+0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1460.336-0.190
TTM0.1980.334-0.136
YOY0.1110.271-0.160
5Y0.0980.366-0.268
10Y0.0910.389-0.298
1.4.2. Debt to Equity Ratio

Measures if Ascelia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ascelia to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.1% means that company has kr0.17 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ascelia Pharma AB (publ):

  • The MRQ is 0.171. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.248. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.171TTM0.248-0.077
TTM0.248YOY0.127+0.121
TTM0.2485Y0.114+0.134
5Y0.11410Y0.105+0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1710.382-0.211
TTM0.2480.397-0.149
YOY0.1270.341-0.214
5Y0.1140.432-0.318
10Y0.1050.465-0.360

2. Market Valuation of Ascelia Pharma AB (publ)

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Ascelia generates.

  • Above 15 is considered overpriced but always compare Ascelia to the Biotechnology industry mean.
  • A PE ratio of -2.68 means the investor is paying kr-2.68 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ascelia Pharma AB (publ):

  • The EOD is -10.160. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.683. Based on the earnings, the company is expensive. -2
  • The TTM is -2.807. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.160MRQ-2.683-7.477
MRQ-2.683TTM-2.807+0.123
TTM-2.807YOY-5.732+2.926
TTM-2.8075Y-8.664+5.857
5Y-8.66410Y-7.534-1.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.160-2.262-7.898
MRQ-2.683-2.599-0.084
TTM-2.807-2.674-0.133
YOY-5.732-4.133-1.599
5Y-8.664-6.258-2.406
10Y-7.534-6.171-1.363
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ascelia Pharma AB (publ):

  • The EOD is -6.761. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.786. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.409. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.761MRQ-1.786-4.976
MRQ-1.786TTM-2.409+0.624
TTM-2.409YOY-5.240+2.831
TTM-2.4095Y-11.390+8.981
5Y-11.39010Y-9.904-1.486
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.761-2.913-3.848
MRQ-1.786-3.275+1.489
TTM-2.409-3.508+1.099
YOY-5.240-5.620+0.380
5Y-11.390-8.306-3.084
10Y-9.904-8.854-1.050
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ascelia is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.53 means the investor is paying kr1.53 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Ascelia Pharma AB (publ):

  • The EOD is 5.795. Based on the equity, the company is overpriced. -1
  • The MRQ is 1.531. Based on the equity, the company is underpriced. +1
  • The TTM is 3.006. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD5.795MRQ1.531+4.265
MRQ1.531TTM3.006-1.475
TTM3.006YOY2.773+0.233
TTM3.0065Y3.328-0.322
5Y3.32810Y2.894+0.434
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.7951.858+3.937
MRQ1.5312.090-0.559
TTM3.0062.091+0.915
YOY2.7732.866-0.093
5Y3.3283.488-0.160
10Y2.8943.836-0.942
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ascelia Pharma AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.303-0.789+160%-0.556+83%-0.040-87%0.096-417%
Book Value Per Share--2.2022.997-27%6.978-68%7.051-69%6.550-66%
Current Ratio--2.3032.619-12%7.674-70%11.022-79%10.639-78%
Debt To Asset Ratio--0.1460.198-26%0.111+31%0.098+49%0.091+61%
Debt To Equity Ratio--0.1710.248-31%0.127+35%0.114+50%0.105+64%
Dividend Per Share----0%-0%-0%-0%
Eps---0.314-0.801+155%-0.967+208%-0.774+147%-0.700+123%
Free Cash Flow Per Share---0.472-0.930+97%-0.922+95%-0.742+57%-0.666+41%
Free Cash Flow To Equity Per Share---0.478-0.937+96%-0.930+94%-0.037-92%0.481-200%
Gross Profit Margin--0.9151.065-14%1.126-19%1.080-15%1.069-14%
Intrinsic Value_10Y_max---11.379--------
Intrinsic Value_10Y_min---10.743--------
Intrinsic Value_1Y_max---3.214--------
Intrinsic Value_1Y_min---3.158--------
Intrinsic Value_3Y_max---8.076--------
Intrinsic Value_3Y_min---7.742--------
Intrinsic Value_5Y_max---11.033--------
Intrinsic Value_5Y_min---10.377--------
Market Cap430748252.000+74%113763449.000332160314.650-66%658274822.250-83%817578371.678-86%710937714.502-84%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio5.795+74%1.5313.006-49%2.773-45%3.328-54%2.894-47%
Pe Ratio-10.160-279%-2.683-2.807+5%-5.732+114%-8.664+223%-7.534+181%
Price Per Share12.760+74%3.3709.718-65%19.358-83%23.825-86%20.718-84%
Price To Free Cash Flow Ratio-6.761-279%-1.786-2.409+35%-5.240+193%-11.390+538%-9.904+455%
Price To Total Gains Ratio-42.065-279%-11.110-11.524+4%-7.665-31%-14.969+35%-14.969+35%
Quick Ratio--1.9352.440-21%7.391-74%12.322-84%11.684-83%
Return On Assets---0.122-0.204+68%-0.130+7%-0.114-6%-0.107-12%
Return On Equity---0.143-0.258+81%-0.150+5%-0.132-7%-0.123-14%
Total Gains Per Share---0.303-0.789+160%-0.556+83%-0.040-87%0.096-417%
Usd Book Value--6830743.2009402702.550-27%21800127.425-69%22205263.980-69%20605418.435-67%
Usd Book Value Change Per Share---0.028-0.073+160%-0.051+83%-0.004-87%0.009-417%
Usd Book Value Per Share--0.2020.275-27%0.641-68%0.648-69%0.602-66%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.029-0.074+155%-0.089+208%-0.071+147%-0.064+123%
Usd Free Cash Flow---1463691.300-2913023.225+99%-2877917.425+97%-2338276.030+60%-2097733.374+43%
Usd Free Cash Flow Per Share---0.043-0.085+97%-0.085+95%-0.068+57%-0.061+41%
Usd Free Cash Flow To Equity Per Share---0.044-0.086+96%-0.085+94%-0.003-92%0.044-200%
Usd Market Cap39585764.359+74%10454860.96330525532.916-66%60495456.165-83%75135452.357-86%65335175.963-84%
Usd Price Per Share1.173+74%0.3100.893-65%1.779-83%2.190-86%1.904-84%
Usd Profit---974048.100-2510868.825+158%-3014825.450+210%-2440606.680+151%-2197708.587+126%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.028-0.073+160%-0.051+83%-0.004-87%0.009-417%
 EOD+5 -3MRQTTM+19 -11YOY+16 -145Y+9 -2110Y+9 -21

3.2. Fundamental Score

Let's check the fundamental score of Ascelia Pharma AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.160
Price to Book Ratio (EOD)Between0-15.795
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.935
Current Ratio (MRQ)Greater than12.303
Debt to Asset Ratio (MRQ)Less than10.146
Debt to Equity Ratio (MRQ)Less than10.171
Return on Equity (MRQ)Greater than0.15-0.143
Return on Assets (MRQ)Greater than0.05-0.122
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Ascelia Pharma AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose13.280
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Selling General Administrative  8603,4254,2858035,088-1594,929-10,285-5,356
Selling and Marketing Expenses  3,780-8842,8962,9615,857-3,2682,589-3,494-905
Interest Expense  21846867-510357121478-2,180-1,702



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets87,072
Total Liabilities12,744
Total Stockholder Equity74,328
 As reported
Total Liabilities 12,744
Total Stockholder Equity+ 74,328
Total Assets = 87,072

Assets

Total Assets87,072
Total Current Assets28,937
Long-term Assets58,135
Total Current Assets
Cash And Cash Equivalents 21,854
Net Receivables 2,461
Other Current Assets 4,622
Total Current Assets  (as reported)28,937
Total Current Assets  (calculated)28,937
+/-0
Long-term Assets
Property Plant Equipment 1,061
Intangible Assets 57,074
Long-term Assets  (as reported)58,135
Long-term Assets  (calculated)58,135
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,567
Long-term Liabilities177
Total Stockholder Equity74,328
Total Current Liabilities
Short-term Debt 884
Accounts payable 1,525
Other Current Liabilities 10,158
Total Current Liabilities  (as reported)12,567
Total Current Liabilities  (calculated)12,567
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt176
Long-term Liabilities  (as reported)177
Long-term Liabilities  (calculated)176
+/- 1
Total Stockholder Equity
Common Stock34,871
Retained Earnings -639,962
Accumulated Other Comprehensive Income 671
Other Stockholders Equity 678,748
Total Stockholder Equity (as reported)74,328
Total Stockholder Equity (calculated)74,328
+/-0
Other
Capital Stock34,871
Cash and Short Term Investments 21,854
Common Stock Shares Outstanding 33,743
Liabilities and Stockholders Equity 87,072
Net Debt -20,793
Net Invested Capital 74,328
Net Working Capital 16,369
Property Plant and Equipment Gross 4,639
Short Long Term Debt Total 1,061



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
0
0
116,149
0
105,463
279,158
287,420
273,082
250,226
236,172
309,273
288,955
255,374
438,033
389,725
365,044
333,493
307,501
283,088
254,090
218,569
180,281
139,296
106,369
87,072
87,072106,369139,296180,281218,569254,090283,088307,501333,493365,044389,725438,033255,374288,955309,273236,172250,226273,082287,420279,158105,4630116,14900
   > Total Current Assets 
0
0
59,082
0
48,399
222,093
230,078
215,770
192,949
176,740
250,005
229,910
196,324
379,193
330,263
305,874
274,611
249,139
224,990
196,148
160,869
121,291
80,575
47,988
28,937
28,93747,98880,575121,291160,869196,148224,990249,139274,611305,874330,263379,193196,324229,910250,005176,740192,949215,770230,078222,09348,399059,08200
       Cash And Cash Equivalents 
0
0
55,063
0
42,111
219,146
149,972
129,814
108,516
102,815
76,981
151,438
184,686
165,422
319,014
291,029
261,599
232,603
208,861
179,811
149,555
111,371
70,500
38,992
21,854
21,85438,99270,500111,371149,555179,811208,861232,603261,599291,029319,014165,422184,686151,43876,981102,815108,516129,814149,972219,14642,111055,06300
       Short-term Investments 
0
0
0
0
0
0
75,076
75,462
75,711
66,488
67,883
69,301
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000069,30167,88366,48875,71175,46275,076000000
       Net Receivables 
0
0
0
0
1,666
1,616
3,927
1,327
1,422
2,169
100,923
2,214
2,833
207,298
5,128
6,584
5,874
6,770
8,872
8,805
5,163
6,463
6,620
5,957
2,461
2,4615,9576,6206,4635,1638,8058,8726,7705,8746,5845,128207,2982,8332,214100,9232,1691,4221,3273,9271,6161,6660000
       Other Current Assets 
0
0
4,019
0
6,288
2,947
5,030
10,494
8,722
7,437
105,141
9,171
11,638
213,771
11,249
14,845
13,012
16,536
16,129
-1
-1
-1
3,455
1
4,622
4,62213,455-1-1-116,12916,53613,01214,84511,249213,77111,6389,171105,1417,4378,72210,4945,0302,9476,28804,01900
   > Long-term Assets 
0
0
57,067
0
57,065
57,065
57,342
57,312
57,277
59,431
59,269
59,045
59,050
58,840
59,462
59,170
58,882
58,362
58,098
57,942
57,700
58,990
58,721
58,381
58,135
58,13558,38158,72158,99057,70057,94258,09858,36258,88259,17059,46258,84059,05059,04559,26959,43157,27757,31257,34257,06557,065057,06700
       Property Plant Equipment 
0
0
0
0
0
0
275
243
212
2,358
2,202
1,978
1,989
1,776
2,400
2,107
1,819
1,297
1,029
870
626
1,914
1,638
1,303
1,061
1,0611,3031,6381,9146268701,0291,2971,8192,1072,4001,7761,9891,9782,2022,358212243275000000
       Long Term Investments 
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000010000
       Intangible Assets 
0
0
57,066
0
57,064
57,065
57,067
57,069
57,065
57,073
57,066
57,067
57,061
57,064
57,062
57,063
57,063
57,065
57,069
57,072
57,074
57,076
57,082
57,078
57,074
57,07457,07857,08257,07657,07457,07257,06957,06557,06357,06357,06257,06457,06157,06757,06657,07357,06557,06957,06757,06557,064057,06600
       Other Assets 
0
0
0
0
-1
0
0
0
0
118,863
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
001010000000000118,8630000-10000
> Total Liabilities 
0
0
4,419
0
4,447
9,375
11,345
9,506
13,164
15,039
25,585
18,341
19,318
38,624
21,843
23,793
25,659
27,107
25,773
23,795
37,710
35,594
33,621
21,801
12,744
12,74421,80133,62135,59437,71023,79525,77327,10725,65923,79321,84338,62419,31818,34125,58515,03913,1649,50611,3459,3754,44704,41900
   > Total Current Liabilities 
0
0
4,419
0
4,447
9,375
11,199
9,391
13,069
13,679
24,408
17,348
18,362
37,871
20,749
22,971
25,106
26,839
25,569
23,556
37,518
34,739
33,011
21,420
12,567
12,56721,42033,01134,73937,51823,55625,56926,83925,10622,97120,74937,87118,36217,34824,40813,67913,0699,39111,1999,3754,44704,41900
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
822
832
1,105
1,106
1,102
871
673
483
291
953
961
885
884
8848859619532914836738711,1021,1061,105832822000000000000
       Accounts payable 
0
0
634
0
611
2,842
4,267
3,684
5,236
4,128
5,282
4,833
3,884
6,963
9,085
8,264
6,147
4,894
8,923
3,858
15,881
8,102
6,497
4,618
1,525
1,5254,6186,4978,10215,8813,8588,9234,8946,1478,2649,0856,9633,8844,8335,2824,1285,2363,6844,2672,842611063400
       Other Current Liabilities 
0
0
3,785
0
3,836
6,533
6,932
5,707
7,833
9,551
19,126
12,515
13,656
30,076
10,559
13,601
17,857
21,074
15,973
19,215
21,346
25,684
2,107
2,062
10,158
10,1582,0622,10725,68421,34619,21515,97321,07417,85713,60110,55930,07613,65612,51519,1269,5517,8335,7076,9326,5333,83603,78500
   > Long-term Liabilities 
0
0
0
0
0
0
146
115
95
1,360
1,177
993
956
753
1,094
822
553
268
204
239
192
855
610
381
177
1773816108551922392042685538221,0947539569931,1771,36095115146000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
992
956
753
1,094
822
553
268
204
240
193
855
610
381
0
03816108551932402042685538221,09475395699200000000000
       Other Liabilities 
0
0
0
0
0
0
0
-1
-1
0
0
1
0
0
0
0
0
0
0
-1
-1
0
0
0
0
0000-1-10000000100-1-10000000
> Total Stockholder Equity
0
0
111,730
111,730
101,016
269,783
276,075
263,576
237,062
221,133
283,688
270,614
236,056
399,409
367,882
341,251
307,834
280,394
257,315
230,295
180,859
144,687
105,675
84,568
74,328
74,32884,568105,675144,687180,859230,295257,315280,394307,834341,251367,882399,409236,056270,614283,688221,133237,062263,576276,075269,783101,016111,730111,73000
   Common Stock
0
0
14,607
0
14,607
22,607
23,489
23,489
23,489
23,489
23,999
28,697
28,697
29,179
34,576
34,576
34,576
34,871
34,871
34,871
34,871
34,871
34,871
34,871
34,871
34,87134,87134,87134,87134,87134,87134,87134,87134,57634,57634,57629,17928,69728,69723,99923,48923,48923,48923,48922,60714,607014,60700
   Retained Earnings Total Equity0000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65
327
150
671
67115032765000000000000000000000
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
213,700
0
213,699
385,693
405,061
0
405,061
405,061
1
493,731
493,731
684,011
678,831
678,831
679,085
679,181
679,426
679,129
679,466
678,748
678,747
678,748
678,748
678,748678,748678,747678,748679,466679,129679,426679,181679,085678,831678,831684,011493,731493,7311405,061405,0610405,061385,693213,6990213,70000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,049
Gross Profit-1,049-1,049
 
Operating Income (+$)
Gross Profit-1,049
Operating Expense-110,429
Operating Income-111,478-111,478
 
Operating Expense (+$)
Research Development81,266
Selling General Administrative30,285
Selling And Marketing Expenses0
Operating Expense110,429111,551
 
Net Interest Income (+$)
Interest Income11,692
Interest Expense-2,418
Other Finance Cost-22,647
Net Interest Income-13,373
 
Pretax Income (+$)
Operating Income-111,478
Net Interest Income-13,373
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-109,607-113,349
EBIT - interestExpense = -113,896
-109,607
-106,870
Interest Expense2,418
Earnings Before Interest and Taxes (EBIT)-111,478-107,189
Earnings Before Interest and Taxes (EBITDA)-110,429
 
After tax Income (+$)
Income Before Tax-109,607
Tax Provision--66
Net Income From Continuing Ops-152,070-109,541
Net Income-109,288
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses111,478
Total Other Income/Expenses Net1,87113,373
 

Technical Analysis of Ascelia
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ascelia. The general trend of Ascelia is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ascelia's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ascelia Pharma AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 16.54 < 17.08 < 17.48.

The bearish price targets are: 11.16 > 10.90 > 8.5.

Tweet this
Ascelia Pharma AB (publ) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ascelia Pharma AB (publ). The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ascelia Pharma AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartAscelia Pharma AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ascelia Pharma AB (publ). The current adx is .

Ascelia Pharma AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Relative Strength Index (RSI) ChartAscelia Pharma AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Stochastic Oscillator ChartAscelia Pharma AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Commodity Channel Index (CCI) ChartAscelia Pharma AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Chande Momentum Oscillator (CMO) ChartAscelia Pharma AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Williams %R ChartAscelia Pharma AB (publ) Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Average True Range (ATR) ChartAscelia Pharma AB (publ) Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily On-Balance Volume (OBV) ChartAscelia Pharma AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ascelia Pharma AB (publ).

Ascelia Pharma AB (publ) Daily Money Flow Index (MFI) ChartAscelia Pharma AB (publ) Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ascelia Pharma AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside

6.3. Candlestick Patterns

Ascelia Pharma AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ascelia Pharma AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose13.280
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ascelia with someone you think should read this too:
  • Are you bullish or bearish on Ascelia? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ascelia? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ascelia Pharma AB (publ)

I send you an email if I find something interesting about Ascelia Pharma AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about Ascelia Pharma AB (publ).

Receive notifications about Ascelia Pharma AB (publ) in your mailbox!